statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company ), a metabolic therapeutics company focused on pioneering new approaches for the treatment of...

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Fractyl Health reports Q4 EPS ($11.18) vs ($7.39) last year

Received IDE approval for the Revita Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal...

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Fractyl Health, Inc. (GUTS) just unveiled an update.

Fractyl Health, Inc. has announced a significant milestone with the FDA granting it Investigational Device Exemption to explore the effectiveness...

Fractyl Health Gains FDA Nod to Investigate Revita Device

Fractyl Health receives FDA IDE approval for Revita Remain-1 pivotal study

Revita aims to be the first approved therapeutic option for durable weight maintenance after discontinuation of GLP-1 based drugs, as an adjunct to diet and exercise With this FDA IDE approval...

Fractyl Health Receives FDA IDE Approval for the Revita  Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

Fractyl Health, Inc. (NASDAQ:GUTS  Get Free Report)s stock price was down 6.2% during trading on Wednesday . The company traded as low as $7.10 and last traded at $7.20. Approximately...

Fractyl Health (NASDAQ:GUTS) Stock Price Down 6.2%

Fractyl Health announces results from Rejuva platform

Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancreatic GLP-1 to provide metabolic control...

UPDATE -- Fractyl Health Announces New Results From Its Rejuva  Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Morgan Stanley assumed coverage on shares of Fractyl Health (NASDAQ:GUTS  Free Report) in a research report report published on Tuesday morning, MarketBeat reports. The brokerage issued an...

Fractyl Health (NASDAQ:GUTS) Now Covered by Morgan Stanley

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Watchers	319
52-Wk Low	$5.75
52-Wk High	$15.00

Volume	191,421.00
52-Wk High	$15.00
52-Wk Low	$5.75

GUTS Fractyl Health Inc.

About

Feed

News

Sentiment

Fundamentals